Generex Biotechnology Corp Story

Requested story not found. it has been either deleted or moved. View all stories for Generex Biotechnology Corp.

Generex Biotechnology Latest Timeline

Generex Biotechnology is listed for 0.0001. The company currently holds 499.66 K in liabilities. Generex Biotechnology has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Generex Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, Generex Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Generex Biotechnology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Generex to invest in growth at high rates of return. When we think about Generex Biotechnology's use of debt, we should always consider it together with cash and equity.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Generex Biotechnology information on this page should be used as a complementary analysis to other Generex Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

If you are still planning to invest in Generex Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Generex Biotechnology's history and understand the potential risks before investing.